GSK 1614235
Alternative Names: 1614235; DSP-3235; GSK1614235; KGA; KGA-3235Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Kissei Pharmaceutical
- Developer GSK; Sumitomo Pharma
- Class Antihyperglycaemics
- Mechanism of Action Sodium-glucose transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in France (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Germany (PO, Tablet)